OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid-use Disorder

Interventions

DEVICE: OXD01 digital therapy
OTHER: Standard of Care

Sponsor

Orexo AB